Literature DB >> 18765511

High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

Lei Ye1, Libero Santarpia, Gilbert J Cote, Adel K El-Naggar, Robert F Gagel.   

Abstract

CONTEXT: Activating mutations in the RET protooncogene have been demonstrated in multiple endocrine neoplasia 2 and sporadic medullary thyroid carcinoma (MTC). However, the complete genetic etiology underlying MTC tumorigenesis remains unclear.
OBJECTIVE: Our objective was to define more precisely the chromosomal regions and uncover novel genes associated with MTC tumorigenesis. DESIGN AND
SETTING: In this study, we used high resolution array-based comparative genomic hybridization to define tumor-associated copy number alterations (CNA) in 30 primary MTCs: 20 sporadic tumors (50% of which harbored RET mutation), and 10 hereditary.
RESULTS: We identified 98 CNA, including 76 genomic allelic losses, two gains, and 20 copy number variations associated with MTC. Across sporadic and hereditary groups, there was a similar and overlapping pattern of predominant allelic loss. There were 29 regions containing at least 30% CNA in the 30 tumor samples. The most frequent allelic loss occurred in four loci, 7q36.1, 12p13.31, 13q12.11, and 19p13.3-11. No regions were found to be uniquely altered in the hereditary tumors. There were 21 CNA specific to sporadic MTC, with loss of 11q23.3 uniquely altered in RET negative tumors. Pathway analysis found cellular growth and proliferation as the most significant overall target, and cell death as the most significant pathway targeted in sporadic MTC.
CONCLUSIONS: Our findings underscore the importance of candidate tumor suppressor genes together with RET alterations in MTCs. Despite of RET status, all MTC might share similar oncogenetic mechanisms. Dysfunction of cell proliferation and cell death may both be involved in MTC tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765511      PMCID: PMC2729231          DOI: 10.1210/jc.2008-0912

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.

Authors:  T Frisk; J Zedenius; J Lundberg; G Wallin; S Kytölä; C Larsson
Journal:  Int J Oncol       Date:  2001-06       Impact factor: 5.650

Review 2.  Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  Nat Clin Pract Oncol       Date:  2006-10

3.  Neuroblastoma--linking a common allele to a rare disease.

Authors:  Brian H Kushner; Nai-Kong V Cheung
Journal:  N Engl J Med       Date:  2008-05-07       Impact factor: 91.245

4.  Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas.

Authors:  S C Huang; C A Koch; A O Vortmeyer; S D Pack; U D Lichtenauer; P Mannan; I A Lubensky; G P Chrousos; R F Gagel; K Pacak; Z Zhuang
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

5.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.

Authors:  C Guo; P S White; M J Weiss; M D Hogarty; P M Thompson; D O Stram; R Gerbing; K K Matthay; R C Seeger; G M Brodeur; J M Maris
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

6.  DNA copy number changes in thyroid carcinoma.

Authors:  S Hemmer; V M Wasenius; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.

Authors:  N Mise; M Drosten; T Racek; A Tannapfel; B M Pützer
Journal:  Oncogene       Date:  2006-05-22       Impact factor: 9.867

Review 8.  Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.

Authors:  Marinella Messina; Bruce G Robinson
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-03

9.  Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions.

Authors:  R Hinze; O Gimm; H Taubert; G Bauer; H Dralle; H J Holzhausen; F W Rath
Journal:  Virchows Arch       Date:  2000-09       Impact factor: 4.064

10.  Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.

Authors:  Wendy van Veelen; Carola J R van Gasteren; Dennis S Acton; David S Franklin; Ruud Berger; Cornelis J M Lips; Jo W M Höppener
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

View more
  15 in total

Review 1.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

Review 2.  Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Authors:  Ying-Hsia Chu; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

3.  Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.

Authors:  Maha El Naofal; Adriel Kim; Hui Yi Yon; Mohamed Baity; Zhao Ming; Jacquelin Bui-Griffith; Zhenya Tang; Melissa Robinson; Elizabeth G Grubbs; Gilbert J Cote; Peter Hu
Journal:  Ann Clin Lab Sci       Date:  2017-09       Impact factor: 1.256

4.  Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure.

Authors:  Megan M McGuire; Wayne Bowden; Natalie J Engel; Hyo Won Ahn; Ertug Kovanci; Aleksandar Rajkovic
Journal:  Fertil Steril       Date:  2011-01-22       Impact factor: 7.329

Review 5.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

6.  Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Authors:  Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

7.  ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Michelle D Williams; Elizabeth G Grubbs; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

8.  The role of Cdk5 in neuroendocrine thyroid cancer.

Authors:  Karine Pozo; Emely Castro-Rivera; Chunfeng Tan; Florian Plattner; Gert Schwach; Veronika Siegl; Douglas Meyer; Ailan Guo; Justin Gundara; Gabriel Mettlach; Edmond Richer; Jonathan A Guevara; Li Ning; Anjali Gupta; Guiyang Hao; Li-Huei Tsai; Xiankai Sun; Pietro Antich; Stanley Sidhu; Bruce G Robinson; Herbert Chen; Fiemu E Nwariaku; Roswitha Pfragner; James A Richardson; James A Bibb
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

9.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

10.  Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Authors:  Ira L Kraft; Srivandana Akshintala; John W Glod; Jack F Shern; Brigitte C Widemann; Yuelin Zhu; Haiyan Lei; Claudia Derse-Anthony; Eva Dombi; Seth M Steinberg; Maya Lodish; Steven G Waguespack; Oxana Kapustina; Elizabeth Fox; Frank M Balis; Maria J Merino; Paul S Meltzer
Journal:  Clin Cancer Res       Date:  2017-11-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.